Biologic modification of animal models of intervertebral disc degeneration

Intervertebral disc degeneration is a chronic process that can become manifest in clinical disorders such as idiopathic low back pain, sciatica, disc herniation, spinal stenosis, and myelopathy. The limited available treatment options (including discectomy and spinal fusion) for these and other disa...

Full description

Saved in:
Bibliographic Details
Published in:Journal of bone and joint surgery. American volume 2006-04, Vol.88 Suppl 2, p.83-87
Main Authors: Larson, 3rd, James W, Levicoff, Eric A, Gilbertson, Lars G, Kang, James D
Format: Article
Language:English
Subjects:
Animals
Biological Products - therapeutic use
Biopsy, Needle
Disease Models, Animal
Genetic Therapy - methods
Immunohistochemistry
Intervertebral Disc - metabolism
Intervertebral Disc - pathology
Intervertebral Disc - physiopathology
Molecular Biology
Pain Measurement
Range of Motion, Articular - physiology
Risk Factors
Sensitivity and Specificity
Spinal Diseases - pathology
Spinal Diseases - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intervertebral disc degeneration is a chronic process that can become manifest in clinical disorders such as idiopathic low back pain, sciatica, disc herniation, spinal stenosis, and myelopathy. The limited available treatment options (including discectomy and spinal fusion) for these and other disabling conditions that arise from intervertebral disc degeneration are highly invasive, achieve limited success, and only address acute symptoms while doing nothing to halt the process of degeneration. Although the precise pathophysiology of intervertebral disc degeneration has yet to be clearly delineated, the progressive decline in aggrecan, the primary proteoglycan of the nucleus pulposus, appears to be a final common pathway. Animal models as well as in vitro studies of the process of disc degeneration have yielded many potentially useful targets for the reversal of disc degeneration. One current research trend is the use of established animal models of disc degeneration to study the role of therapeutic modalities in reversing the process of degeneration, often with use of the delivery of genes or gene products that influence the anabolic and catabolic pathways of the disc. This article reviews the ability of gene-product delivery systems and gene therapy to alter biologic processes in animal models of disc degeneration and examines future trends in this field.
ISSN:0021-9355
DOI:10.2106/00004623-200604002-00017